Y.Ni, S. Sun, I. Oparaocha, L. Humeau, B. Davis, R. Cohen, G. Binder, Y.-N. Chan, V. Slepushkin, and B. Dropulic, ‘Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector’Journal of Gene Medicine, 2005; Vol. 7, No. 6, 818-834

2005 ◽  
Vol 7 (6) ◽  
pp. 835-835
Keyword(s):  
Cell Line ◽  
Large Scale ◽  
High Titer ◽  
Scale Production ◽  
Packaging Cell Line ◽  
Packaging Cell ◽  
Large Scale Production ◽  
Hiv 1

Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector

2005 ◽  
Vol 7 (6) ◽  
pp. 818-834 ◽  
Author(s):  
Yajin Ni ◽  
Susan Sun ◽  
Ibe Oparaocha ◽  
Laurent Humeau ◽  
Brian Davis ◽  
...  
Keyword(s):  
Cell Line ◽  
Large Scale ◽  
Lentiviral Vector ◽  
High Titer ◽  
Scale Production ◽  
Packaging Cell Line ◽  
Packaging Cell ◽  
Large Scale Production ◽  
Hiv 1

scholarly journals A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors

2006 ◽  
Vol 14 (2) ◽  
pp. 276-284 ◽  
Author(s):  
Adam S. Cockrell ◽  
Hong Ma ◽  
Kailing Fu ◽  
Thomas J. McCown ◽  
Tal Kafri
Keyword(s):  
Cell Line ◽  
High Titer ◽  
Packaging Cell Line ◽  
Packaging Cell ◽  
Hiv 1

scholarly journals Cyanobacteria—From the Oceans to the Potential Biotechnological and Biomedical Applications

Marine Drugs ◽  
2021 ◽  
Vol 19 (5) ◽  
pp. 241
Author(s):  
Shaden A. M. Khalifa ◽  
Eslam S. Shedid ◽  
Essa M. Saied ◽  
Amir Reza Jassbi ◽  
Fatemeh H. Jamebozorgi ◽  
...  
Keyword(s):  
Bioactive Compounds ◽  
Biomedical Applications ◽  
Large Scale ◽  
Biological Activities ◽  
Scale Production ◽  
Pharmacological Activities ◽  
Large Scale Production ◽  
Marine Products ◽  
Hiv 1 ◽  
Successful Phase

Cyanobacteria are photosynthetic prokaryotic organisms which represent a significant source of novel, bioactive, secondary metabolites, and they are also considered an abundant source of bioactive compounds/drugs, such as dolastatin, cryptophycin 1, curacin toyocamycin, phytoalexin, cyanovirin-N and phycocyanin. Some of these compounds have displayed promising results in successful Phase I, II, III and IV clinical trials. Additionally, the cyanobacterial compounds applied to medical research have demonstrated an exciting future with great potential to be developed into new medicines. Most of these compounds have exhibited strong pharmacological activities, including neurotoxicity, cytotoxicity and antiviral activity against HCMV, HSV-1, HHV-6 and HIV-1, so these metabolites could be promising candidates for COVID-19 treatment. Therefore, the effective large-scale production of natural marine products through synthesis is important for resolving the existing issues associated with chemical isolation, including small yields, and may be necessary to better investigate their biological activities. Herein, we highlight the total synthesized and stereochemical determinations of the cyanobacterial bioactive compounds. Furthermore, this review primarily focuses on the biotechnological applications of cyanobacteria, including applications as cosmetics, food supplements, and the nanobiotechnological applications of cyanobacterial bioactive compounds in potential medicinal applications for various human diseases are discussed.

scholarly journals Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges

Pharmaceutics ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 1051
Author(s):  
Eduardo Martínez-Molina ◽  
Carlos Chocarro-Wrona ◽  
Daniel Martínez-Moreno ◽  
Juan A. Marchal ◽  
Houria Boulaiz
Keyword(s):  
Viral Vectors ◽  
Large Scale ◽  
Lentiviral Vectors ◽  
Good Manufacturing Practice ◽  
Scale Production ◽  
Gene Therapies ◽  
Packaging Cell ◽  
Large Scale Production ◽  
Target Production

Lentiviral vectors (LVs) have gained value over recent years as gene carriers in gene therapy. These viral vectors are safer than what was previously being used for gene transfer and are capable of infecting both dividing and nondividing cells with a long-term expression. This characteristic makes LVs ideal for clinical research, as has been demonstrated with the approval of lentivirus-based gene therapies from the Food and Drug Administration and the European Agency for Medicine. A large number of functional lentiviral particles are required for clinical trials, and large-scale production has been challenging. Therefore, efforts are focused on solving the drawbacks associated with the production and purification of LVsunder current good manufacturing practice. In recent years, we have witnessed the development and optimization of new protocols, packaging cell lines, and culture devices that are very close to reaching the target production level. Here, we review the most recent, efficient, and promising methods for the clinical-scale production ofLVs.

Large-scale production, purification and immunological analysis of vaccinia recombinant derived HIV-1 gp160

Vaccine ◽  
1989 ◽  
Vol 7 (2) ◽  
pp. 189
Author(s):  
N. Barrett ◽  
A. Mitterer ◽  
J. Eibl ◽  
M. Eibl ◽  
B. Moss ◽  
...  
Keyword(s):  
Large Scale ◽  
Scale Production ◽  
Immunological Analysis ◽  
Large Scale Production ◽  
Hiv 1

Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gp160 and Analysis of Its Immunogenicity

1989 ◽  
Vol 5 (2) ◽  
pp. 159-171 ◽  
Author(s):  
NOEL BARRETT ◽  
ARTUR MITTERER ◽  
WOLFGANG MUNDT ◽  
JOHANN EIBL ◽  
MARTHA EIBL ◽  
...  
Keyword(s):  
Large Scale ◽  
Scale Production ◽  
Large Scale Production ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document